Tags

Type your tag names separated by a space and hit enter

Utility and limitations of Addenbrooke's Cognitive Examination-Revised for detecting mild cognitive impairment in Parkinson's disease.
Dement Geriatr Cogn Disord. 2011; 31(5):349-57.DG

Abstract

BACKGROUND/AIMS

To evaluate the utility of the Addenbrooke's Cognitive Examination-Revised (ACE-R) as a screening tool for mild cognitive impairment in Parkinson's disease (PD-MCI).

METHODS

PD patients underwent comprehensive neuropsychological and neurological evaluations and ACE-R assessment.

RESULTS

The ACE-R was superior to the Mini-Mental State Exam (MMSE) in detecting PD-MCI, with a cutoff score of ≤93 offering a sensitivity of 61% and a specificity of 64%. The utility of the ACE-R in detecting PD-MCI is largely influenced by the fluency sub-domain score, and has optimal discriminability when utilized in patients with lower levels of education (≤12 years of formal schooling).

CONCLUSION

The ACE-R must be used cautiously as a screening tool for PD-MCI, with results being most influenced by its fluency sub-domain score and patient education levels.

Authors+Show Affiliations

University of New South Wales and Neuroscience Research Australia, Sydney, N.S.W.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Validation Study

Language

eng

PubMed ID

21613789

Citation

Komadina, Natalie C., et al. "Utility and Limitations of Addenbrooke's Cognitive Examination-Revised for Detecting Mild Cognitive Impairment in Parkinson's Disease." Dementia and Geriatric Cognitive Disorders, vol. 31, no. 5, 2011, pp. 349-57.
Komadina NC, Terpening Z, Huang Y, et al. Utility and limitations of Addenbrooke's Cognitive Examination-Revised for detecting mild cognitive impairment in Parkinson's disease. Dement Geriatr Cogn Disord. 2011;31(5):349-57.
Komadina, N. C., Terpening, Z., Huang, Y., Halliday, G. M., Naismith, S. L., & Lewis, S. J. (2011). Utility and limitations of Addenbrooke's Cognitive Examination-Revised for detecting mild cognitive impairment in Parkinson's disease. Dementia and Geriatric Cognitive Disorders, 31(5), 349-57. https://doi.org/10.1159/000328165
Komadina NC, et al. Utility and Limitations of Addenbrooke's Cognitive Examination-Revised for Detecting Mild Cognitive Impairment in Parkinson's Disease. Dement Geriatr Cogn Disord. 2011;31(5):349-57. PubMed PMID: 21613789.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Utility and limitations of Addenbrooke's Cognitive Examination-Revised for detecting mild cognitive impairment in Parkinson's disease. AU - Komadina,Natalie C, AU - Terpening,Zoe, AU - Huang,Yue, AU - Halliday,Glenda M, AU - Naismith,Sharon L, AU - Lewis,Simon J G, Y1 - 2011/05/25/ PY - 2011/04/04/accepted PY - 2011/5/27/entrez PY - 2011/5/27/pubmed PY - 2011/11/16/medline SP - 349 EP - 57 JF - Dementia and geriatric cognitive disorders JO - Dement Geriatr Cogn Disord VL - 31 IS - 5 N2 - BACKGROUND/AIMS: To evaluate the utility of the Addenbrooke's Cognitive Examination-Revised (ACE-R) as a screening tool for mild cognitive impairment in Parkinson's disease (PD-MCI). METHODS: PD patients underwent comprehensive neuropsychological and neurological evaluations and ACE-R assessment. RESULTS: The ACE-R was superior to the Mini-Mental State Exam (MMSE) in detecting PD-MCI, with a cutoff score of ≤93 offering a sensitivity of 61% and a specificity of 64%. The utility of the ACE-R in detecting PD-MCI is largely influenced by the fluency sub-domain score, and has optimal discriminability when utilized in patients with lower levels of education (≤12 years of formal schooling). CONCLUSION: The ACE-R must be used cautiously as a screening tool for PD-MCI, with results being most influenced by its fluency sub-domain score and patient education levels. SN - 1421-9824 UR - https://www.unboundmedicine.com/medline/citation/21613789/Utility_and_limitations_of_Addenbrooke's_Cognitive_Examination_Revised_for_detecting_mild_cognitive_impairment_in_Parkinson's_disease_ L2 - https://www.karger.com?DOI=10.1159/000328165 DB - PRIME DP - Unbound Medicine ER -